ID: 134: Development of sample type specific surrogate matrices for dilution of blood samples to overcome matrix effects in multiplexing immunoassays

详细信息    查看全文

• 作者：Markus Miholits ; Ricarda Heintz ; Katharina Mueller-Hartburg
• 刊名：Cytokine
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：76
• 期：1
• 页码：91
• 全文大小：45 K

文摘

Beside the advantage of bead-based multiplex immunoassays being a high-throughput screening tool, saving time and sample volume and generating confer data that are internally consistent by sample, additional requirements in this technology are getting more and more important: since in recent years multiplexing assays got widespread in the clinical research field, the need of performance specifications comparable to those of classical ELISA assays – which are still the “golden standard” of immunoassays – is growing.

Benchmark analysis of bead-based multiplex immunoassays from different vendors and different platforms all showed up the same limitations for these assays in regards of spike- and dilution-recovery performance in blood samples. Due to the complexities of the matrix, both serum and plasma show to inhibit the readout of many cytokines (low spike recovery) with some variations between different donors and also with differences between serum and plasma. Some of these data also conclude that dilution of samples should not be assumed to be linear.

eBioscience/Affymetrix took the advantage of its long year expertise in high-validated immunoassay development to develop matrix type specific sample diluents for serum and plasma to overcome described matrix- and multiplexing-effects and to fulfill high performance specifications comparable to those of traditional ELISA.

The newly developed surrogate matrices for dilution of serum or plasma samples give spike- and dilution-recovery results in the range of 70–130% and help to fulfill these specifications over the broadest individual assay range, with lowest variation between individual donors and the broadest portfolio on the market.